Vice President, Clinical Operations

Pre-clinical and non-human study design and management by MSA

Tim Warneke brings to Mesa Science Associates over 20 years of pharmaceutical development experience. These experiences range across large (Ciba-Geigy and Abbott Laboratories) to mid-size (King Pharmaceuticals) pharmaceutical companies and the world’s largest contract research organization (Quintiles).

Mr. Warneke has leveraged his expert knowledge of the Code of Federal Regulations, ICH Guidelines, Good Clinical Practice, and Good Laboratory Practice to provide operational excellence in support of numerous INDs and NDAs throughout his career. Operationally focused, he has been responsible for clinical study conduct across all phases of pharmaceutical development from single-center studies to large multi-national clinical trials utilizing a wide array of therapeutic areas including:

Cardiology/Vascular Diseases, Dermatology, Devices, Endocrinology, Gastroenterology, Healthy Volunteers, Hepatology (Liver, Pancreatic, Gall Bladder), Infections and Infectious Diseases, Musculoskeletal, Nephrology, Neurology, Oncology, Orthopedics/Orthopedic Surgery, Pediatrics Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Vaccines

Mr. Warneke began his career at Northwestern University in the Department of Community Health and Preventive Medicine, coordinating the clinical activities of the landmark NHLBI funded CARDIA study from its initial year in 1983 to 1988.

MSA News

Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.

May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…

Read More

Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis

The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….

Read More

Mesa Science Associates and Bryn Pharma Publish Pre-Clinical Study of a New Approach to Treating Anaphylaxis

April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…

Read More